Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: a subgroup analysis of the JBR10 trial

Adjuvant chemotherapy is underutilized in clinical practice, in part, because its anticipated survival benefit is 6%. We evaluated the impact of AC on overall and recurrence-free survival among completely resected pN1 NSCLC patients enrolled in the North American Intergroup phase III (JBR10) trial. A post-hoc subgroup analysis of pN1 NSCLC patients was performed. Participants were randomized to cisplatin+vinorelbine (AC) (n=118) or observation (n=116) following complete resection. The primary endpoint was overall survival (OS).
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: THORACIC – Original Submission Source Type: research